Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • Worldwide study of hematopoiet...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency

Bibliographic Details
Published in:Haematologica
Main Authors: Stephanie van Straaten, Marc Bierings, Paola Bianchi, Kensuke Akiyoshi, Hitoshi Kanno, Isabel Badell Serra, Jing Chen, Xiaohang Huang, Eduard van Beers, Supachai Ekwattanakit, Tayfun Güngör, Wijnanda Adriana Kors, Frans Smiers, Reinier Raymakers, Lucrecia Yanez, Julian Sevilla, Wouter van Solinge, Jose Carlos Segovia, Richard van Wijk
Format: Article
Language:English
Published: Ferrata Storti Foundation 2018-02-01
Online Access:https://haematologica.org/article/view/8370
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://haematologica.org/article/view/8370

Similar Items

  • Untargeted metabolic profiling in dried blood spots identifies disease fingerprint for pyruvate kinase deficiency
    by: Birgit van Dooijeweert, et al.
    Published: (2020-09-01)
  • AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes
    by: Minke A.E. Rab, et al.
    Published: (2020-01-01)
  • P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
    by: Myrthe van Dijk, et al.
    Published: (2023-08-01)
  • The variable manifestations of disease in pyruvate kinase deficiency and their management
    by: Hanny Al-Samkari, et al.
    Published: (2020-03-01)
  • PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
    by: VAN DIJK M., et al.
    Published: (2022-08-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs